KOSDAQ - Delayed Quote KRW
AprilBio Co.,Ltd. (397030.KQ)
15,640.00
+240.00
+(1.56%)
As of 11:23:09 AM GMT+9. Market Open.
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Sang-Hoon Cha | Chief Executive Officer | -- | -- | -- |
| Jin-Taek Kim | CFO, Head of Business Management Division & Director of Administration Division | -- | -- | -- |
| Moo Yong Song | CTO & Head of Research & Planning Division | -- | -- | -- |
| Seung Goo Kang | CSO | -- | -- | -- |
| Jae Heung Lee | CDO and Director of R&D Division | -- | -- | -- |
AprilBio Co.,Ltd.
Room 602, Building B
Medical and Bioscience College Gangwon University 1 Gangwon-daehak-gil (Hyoja-dong)
Chuncheon-si, 24341
South Korea
Description
AprilBio Co., Ltd. develops long-acting type biobetter and antibody biologics. The company develops products based on its long-acting protein medicine platform technology. It is developing various products for use in the treatment of rare diseases, cancer, male infertility, autoimmune and inflammatory diseases. The company was founded in 2013 and is headquartered in Chuncheon-si, South Korea.
Corporate Governance
AprilBio Co.,Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available